Montoya ZPC

Language: Spanish
References: 5
Page: 41-43
PDF size: 274.48 Kb.

Text Extraction

No abstract.

REFERENCES

1. Kay MA. Ruvkun and Ambros recognized for miRNAs.Mol Ther Nucleic Acids. 2024 Nov 20;35(4):102379.doi: 10.1016/j.omtn.2024.102379. PMID: 39640011;PMCID: PMC11617852.

2. Ma YM, Zhao L. Mechanism and TherapeuticProspect of miRNAs in Neurodegenerative Diseases.Behav Neurol. 2023 Nov 23;2023:8537296. doi:10.1155/2023/8537296. PMID: 38058356; PMCID:PMC10697780.

3. Alkhazaali-Ali Z, Sahab-Negah S, Boroumand AR,Tavakol-Afshari J. MicroRNA (miRNA) as a biomarkerfor diagnosis, prognosis, and therapeutics molecules inneurodegenerative disease. Biomed Pharmacother. 2024Aug;177:116899. doi: 10.1016/j.biopha.2024.116899.Epub 2024 Jun 17. PMID: 38889636.

4. Sun E, Motolani A, Campos L, Lu T. The PivotalRole of NF-kB in the Pathogenesis and Therapeuticsof Alzheimer's Disease. Int J Mol Sci. 2022 Aug11;23(16):8972. doi: 10.3390/ijms23168972. PMID:36012242; PMCID: PMC9408758.

5. Hong H, Wang Y, Menard M, Buckley JA, Zhou L,Volpicelli-Daley L, Standaert DG, Qin H, BenvenisteEN. Suppression of the JAK/STAT pathway inhibitsneuroinflammation in the line 61-PFF mouse model ofParkinson's disease. J Neuroinflammation. 2024 Sep1;21(1):216. doi: 10.1186/s12974-024-03210-8. PMID:39218899; PMCID: PMC11368013.